Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

Recruiting now

Conditions studied: Alzheimer's Disease (AD)

In brief

With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).

Key facts

Study ID

NCT06924359

Run by

Peking University First Hospital

People needed

200

Starts

2025-03-19

Expected to finish

2027-08-31

Last updated by the study team

2025-04-11

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female participants aged ≥ 50 years;
• Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
• Signed informed consent form

You may not qualify if…

• Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
• Inability to cooperate with cognitive assessments;
• Refusal to undergo blood sampling.

Where it is running

• Peking University First Hospital — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.